The RNAi drug developer tickled investors with promising clinical data.
All of the share price gains came after September -- and for good reason.
These two small-cap biopharmas have promising early-stage drug candidates that could take them far if all goes according to plan.
The pharmaceutical company announced the pricing of a public stock offering. It's wisely taking advantage of a soaring stock price to raise cash ahead of a crucial market launch.
The small-cap pharma sank on an update from its top competitor.
The company's lead drug candidate bested a competitor's therapy on a key endpoint in a phase 3 trial.
These genetic testing stocks took divergent paths in the final months of 2019, but they're solid options for investors with a long-term mindset.
An important drug candidate failed to meet its primary endpoint in a clinical trial. That left the door open for a new competitor.
Two triple-combination therapies delivered impressive results in early-stage studies, which propelled the stock to a 170% gain in 2019.
The company scored an important win in a patent dispute.
These two businesses generate strong cash flow, pay dividends, and have a strong track record of beating the S&P 500.
An extended and reinstated tax credit will create a more than $500 million windfall for the renewable fuels leader in early 2020, but the future beckons.
Impressive long-term study results for an important product eased investor concerns over the tie-up between Exact Sciences and Genomic Health.
The solid end of the year performance meant shares nearly tripled in 2019.
The biopharma stock more than tripled in 2019.
Investors breathed a sign of relief as multiple pipeline assets from Celgene closed the year with positive updates.
The next decade will require a lot of what these two renewable energy companies offer, but investors likely won't have to wait very long.
An important clinical trial failed, reminding investors of the company's poor track record with its pipeline.
These two promising RNAi drug developers are trading at hefty premiums going into 2020.
The small-cap company announced promising results from a clinical trial.